New compound targets drug-resistant HIV mutants
Antiretroviral therapies have worked wonders suppressing HIV replication and its progression to AIDS, but their effectiveness is deteriorating due to the constant development of drug resistance in the virus. Now Yale researchers have shown their newly developed compounds maintain anti-HIV activity against drug-resistant mutants better than FDA-approved medications.
Human insulin as safe and effective to treat type 2 diabetes as costlier insulin analogs
Patients with Type 2 diabetes who were treated with the newer generation of insulin analog drugs did not have substantially better outcomes than those treated with less costly human insulin, according to a study by Yale School of Medicine researchers and colleagues at Kaiser Permanente.
Sanacora speaks on panel that looks at new applications for designer drugs, including ketamine
Gerard Sanacora, MD, PhD, Professor of Psychiatry and Director of the Yale Depression Research Program, spoke on a panel May 30 in Arlington, Va., about new medical applications for common drugs of abuse.
The open-access model: A promising model for scaling up opioid agonist treatment
Lynn Madden, PhD, MPA, Postdoctoral Associate, and Declan Barry, PhD, Associate Professor of Psychiatry, are the first and senior authors, respectively, of a paper published in Addiction which demonstrates the promise of their "open-access model" for treating patients with opioid use disorder.
Making milestones against non-small cell lung cancer
Hard to detect in its early stages and hard to treat as it advances, lung cancer is the leading cause of cancer mortality around the world, with an estimated 1.6 million deaths each year. New treatments, however, are bettering the odds for people with non-small cell lung cancer (NSCLC), which makes up about 85 percent of lung cancer cases.
Crystallizing discovery on a key target for cancer drugs
Many approved cancer therapies target a protein called epidermal growth factor receptor (EGFR) that regulates many crucial cellular processes and can speed the proliferation of tumor cells. Yale Cancer Center scientists now have made a fundamental discovery about EGFR signaling, reported in the journal Cell, that may open the potential for new types of cancer drugs.
Backed by Yale Cancer Center research, FDA approves new immunotherapy drug for stomach cancer
A drug whose clinical testing was led by Charles S. Fuchs, MD, MPH, director of Yale Cancer Center, has become the first immunotherapy treatment for advanced stomach cancer. The drug, pembrolizumab (Keytruda®), was approved by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with advanced stomach cancer showing PD-L1 positive tumors. Pembrolizumab works by increasing the ability of the body’s immune system to help detect and fight tumor cells. In 2017, an estimated 28,000 Americans will be diagnosed with stomach cancer.
A Cancer Conundrum: Too Many Drug Trials, Too Few Patients
With the arrival of two revolutionary treatment strategies, immunotherapy and personalized medicine, cancer researchers have found new hope — and a problem that is perhaps unprecedented in medical research. There are too many experimental cancer drugs in too many clinical trials, and not enough patients to test them on. Immunotherapy trials have proliferated so quickly that major medical centers are declining to furnish patients to them. The Yale Cancer Center participates in fewer than 10 percent of the immunotherapy trials it is asked to join. The problem is that many of the trials are uninteresting from a scientific view, said Dr. Roy Herbst, the center’s chief of medical oncology. The companies sponsoring these trials are not addressing new research questions, he said; they are trying to get proprietary drugs approved.Source: The New York Times
Research Note: Irritability and ADHD medications
Irritability is common across psychiatric diagnoses, but is especially common in children with ADHD. Some common ADHD medications are purported to increase irritability, leading doctors and families to avoid them, even though medication is a highly effective treatment.
Unpredictability the key to “rewiring” our fight against infection: In conversation with Professor John MacMicking
John MacMicking of the Systems Biology Institute talks about his work to integrate abstract and experimental science in an effort to “rewire” the host immune response to infection. Dr. MacMicking is an Investigator of the Howard Hughes Medical Institute (HHMI) and tenured Associate Professor of Microbial Pathogenesis and of Immunobiology at the School of Medicine.Source: Yale West Campus News
Yale School of Medicine holds symposium in New Haven on Connecticut opioid crisis
NEW HAVEN >> The country’s two previous opioid epidemics led to changes in federal laws and policy, but had other unintended effects that likely are helping to fuel the current drug crisis, according to a Yale professor.Source: New Haven Register
Trump wants faster FDA action, but 1 in 3 drugs have safety issues after approval
President Trump wants the Food and Drug Administration to approve drugs faster, but researchers at the Yale School of Medicine found that nearly a third of medications that reached the market from 2001 through 2010 had major safety issues years after they became widely available to patients.Source: STAT